HC Wainwright Forecasts AEON Biopharma FY2026 Earnings

AEON Biopharma, Inc. (NASDAQ:AEON) – Analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for AEON Biopharma in a research note issued on Friday, August 14th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($0.56) per share for the year. HC Wainwright currently has a “Buy” rating and a $1.20 price target on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.77) per share. HC Wainwright also issued estimates for AEON Biopharma’s FY2027 earnings at ($0.25) EPS.

AEON has been the topic of a number of other research reports. Lake Street Capital initiated coverage on AEON Biopharma in a report on Thursday, July 30th. They set a “buy” rating and a $1.00 target price on the stock. Zacks Research raised AEON Biopharma to a “hold” rating in a research note on Wednesday, May 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1.10.

AEON Biopharma Trading Down 7.1%

NASDAQ AEON opened at $0.26 on Tuesday. AEON Biopharma has a 12 month low of $0.22 and a 12 month high of $1.45. The stock has a 50-day simple moving average of $0.47 and a 200 day simple moving average of $0.81. The company has a market capitalization of $6.46 million, a PE ratio of 1.42 and a beta of 0.65.

Hedge Funds Weigh In On AEON Biopharma

An institutional investor recently raised its stake in AEON Biopharma stock. Geode Capital Management LLC lifted its position in AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,134 shares of the company’s stock after buying an additional 13,061 shares during the period. Geode Capital Management LLC owned about 0.51% of AEON Biopharma worth $66,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.